Gene Michael Bennett
Independent
Tenure on this board
New nominee
Meeting calendar
CPHI · Annual meeting · Tuesday, December 30, 2025
China Pharma Holdings Inc
3 nominees · 3 ballot items.
Election of independent directors; authorization of a reverse stock split up to 1:20; and approval of Amendment No. 3 to the Amended and Restated 2010 Long-Term Incentive Plan; with any other business as may properly come before the meeting.
Market cap
$328M
1Y TSR
-40.0%
Board grade
—
Record date
Nov 3, 2025
Filing
DEF 14A
Meeting concluded · Dec 30, 2025
Follow how the vote landed and what changed on China Pharma Holdings Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Independent Directors
ManagementBoard: FORElection of three independent director nominees to the Board of Directors to serve for one year until the next annual meeting and until their successors are elected and qualified.
- 2
Authorize the Board of Directors to Effect a Reverse Stock Split
ManagementBoard: FORTo consider and approve an amendment to the Articles of Incorporation to effect a reverse stock split, at a ratio of up to 1:20, such that every holder of common stock shall receive one share of Common Stock for pro rata twenty shares of Common Stock held, based on the ratio within the specified range.
- 3
Approval of the Amendment No.3 to the Amended and Restated 2010 Long-Term Incentive Plan
ManagementBoard: FORIncrease the number of shares of common stock that may be issued under the Plan by 500,000 shares (from 69,600 to 569,600) and extend the Plan’s term, to provide flexibility to issue equity-based awards to employees, officers, directors and consultants.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
18.5 yrs
Independent
Tenure on this board
18.5 yrs
Ownership
Latest 13F quarterTop institutional holders6
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 0.0% | 12,924 | $8K |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 0.0% | 11,418 | $7K |
| 3 | CITIGROUP INC | 0.0% | 996 | $608 |
| 4 | UBS Group AG | 0.0% | 389 | $237 |
| 5 | EFG International AG | 0.0% | 40 | $24 |
| 6 | DANSKE BANK A/S | 0.0% | 1 | $1 |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at China Pharma Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$279M
Seer IncSEER
Annual meeting·Jul 28, 2026·$112M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$705M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.5B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the China Pharma Holdings Inc 2025 annual meeting?
- China Pharma Holdings Inc (CPHI) holds its 2025 annual shareholder meeting on Tuesday, December 30, 2025.
- What is the record date for the China Pharma Holdings Inc 2025 meeting?
- The record date for the China Pharma Holdings Inc 2025 meeting is Monday, November 3, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for China Pharma Holdings Inc's 2025 meeting?
- The board is presenting 3 director nominees at the China Pharma Holdings Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the China Pharma Holdings Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the China Pharma Holdings Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.